Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. In the U.S., Aerie markets Rhopressa® (netarsudil ophthalmic solution) 0.02%, a Rho kinase (ROCK) inhibitor, and the fixed-dose combination Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. Rhokiinsa® (netarsudil ophthalmic solution) 0.02% has received marketing authorization in the EU. Aerie has development operations in Europe and Japan, as well as a global manufacturing facility in Ireland, and is expanding its pipeline with clinical stage programs in dry eye and retina, and discovery programs based on its proprietary library of small-molecule multi-kinase inhibitors.
Legend
Available Timeslot
Scheduled Appointment
Personal Appointments
Appointment Request
Blocked Timeslot
Restricted Timeslot
For Technical Support with this webpage, please contact support.
For exhibit questions please contact Grayson Lutz.